Symbol not found

NASDAQ:AMGN   00:00AM GMT
0.00
0.00 (0.00%)
Products, Strategic Combinations, Regulatory

Ideaya Announces Clinical Trial Collaboration With Amgen

Published: 07/27/2022 10:36 GMT
AMGEN Inc. (AMGN) - Ideaya Announces Clinical Trial Collaboration With Amgen to Evaluate Mat2a-prmt5 Synthetic Lethality Combination in Mtap Deleted Tumors.
Ideaya Biosciences Inc - Agreement With Amgen to Evaluate Efficacy, Safety of Ide397, With Amg 193 in a Phase 1 Clinical Trial.
Ideaya Biosciences Inc - Ideaya Will Provide Ide397 Drug Supply to Amgen, Who Will Be Sponsor of Phase 1 Clinical Combination Trial.
Ideaya Biosciences Inc - Ideaya and Amgen Will Jointly Share External Costs of Clinical Trial.
Ideaya Biosciences Inc - Ideaya and Amgen Will Jointly Oversee Clinical Development of Combination Therapy.
Ideaya Biosciences Inc - Ideaya and Amgen Each Retain All Commercial Rights to Their Respective Compounds.